News/ News/ Oncology Bayer takes control of Loxo duo as Lilly closes takeover Phil Taylor Bayer, cancer, Loxo 0 Comment Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the Share X Bayer takes control of Loxo duo as Lilly closes takeover https://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
News/ News/ News/ Oncology/ R&D/ Top stories Lilly further boosts cancer pipeline with $8bn Loxo acquisition George Underwood Lilly, Loxo, M&A, Oncology 0 Comment In the second big M&A deal of the year following BMS’s acquisition of Celgene, Eli Lilly has announced Share X Lilly further boosts cancer pipeline with $8bn Loxo acquisition https://pharmaphorum.com/news/lilly-further-boosts-cancer-pipeline-with-8bn-loxo-acquisition/
News/ News/ Oncology/ Top stories Bayer/Loxo drug approved in cancers with certain mutation Richard Staines Bayer, cancer, Loxo 0 Comment The FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific Share X Bayer/Loxo drug approved in cancers with certain mutation https://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
ASCO 2018/ Event coverage/ Oncology/ Views & Analysis/ Views and analysis ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo Richard Staines ASCO 2018, breast cancer, cancer, Loxo, ovarian cancer, Tesaro 0 Comment Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might Share X ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo https://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/
